Genomic and proteomic profiling for cancer diagnosis in dogs by Morris, Joanna S.
 
 
 
 
 
 
Morris, J. S. (2016) Genomic and proteomic profiling for cancer diagnosis 
in dogs. Veterinary Journal, 215, pp. 101-109. 
(doi:10.1016/j.tvjl.2016.01.003) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/123782/ 
     
 
 
 
 
 
 
Deposited on: 2 September 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
1 
 
Commissioned Review Article for Special Issue 1 
 2 
 3 
Genomic and proteomic profiling for cancer diagnosis in dogs  4 
 5 
 6 
Joanna S. Morris * 7 
 8 
University of Glasgow, School of Veterinary Medicine, College of Medical, Veterinary and 9 
Life Sciences, Bearsden, Glasgow, G61 1QH, UK 10 
 11 
 12 
*Corresponding author: Tel: +44 141 330 5848. 13 
E-mail address: joanna.morris@glasgow.ac.uk (J.S. Morris). 14 
  15 
2 
 
Abstract 16 
Global gene expression, whereby tumours are classified according to similar gene 17 
expression patterns or ‘signatures’ regardless of cell morphology or tissue characteristics, is 18 
being increasingly used in both human and veterinary fields to assist in cancer diagnosis and 19 
prognosis. Many studies on canine tumours have focussed on RNA expression using 20 
techniques such as microarrays or next generation sequencing, however, proteomic studies 21 
combining two-dimensional polyacrylamide gel electrophoresis or two-dimensional 22 
differential gel electrophoresis with mass spectrometry have also provided a wealth of data 23 
on gene expression in tumour tissues. In addition, proteomics has been instrumental in the 24 
search for tumour biomarkers in blood and other body fluids.  25 
 26 
Keywords: Biomarkers; Gene expression signatures; Mass spectrometry; Microarray; Next 27 
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Introduction 30 
A diagnosis of ‘cancer’ can be challenging in both dogs and man. Historically, it has 31 
relied on histopathological interpretation of biopsy samples with an emphasis on cell 32 
morphology and tissue architecture, using immunohistochemical (IHC) stains to confirm the 33 
precise cell of origin or specify subtype, to help with treatment decisions and estimates of 34 
prognosis.  35 
 36 
Examination of single gene product expression by IHC can be useful diagnostically 37 
and practical to assess in the clinical laboratory setting, but more recently global gene 38 
expression is being used in both human and veterinary fields. This classifies tumours 39 
according to similar gene expression patterns or ‘signatures’ consisting of several tens or 40 
hundreds of genes, regardless of cell morphology or tissue characteristics. Ultimately, gene 41 
expression patterns from individual tumours may direct personal patient treatment plans, 42 
using therapy targeted to specific pathways of gene expression (Chantrill et al., 2015). The 43 
feasibility of prospective molecular profiling of canine cancers for personalised medicine 44 
(PMed) has already been investigated successfully, making it a practical option for clinical 45 
use (Monks et al., 2013; Paoloni et al., 2014). In the shorter term, genomic profiling can 46 
usefully identify a few key genes for which IHC or RT-PCR assays can be developed for 47 
clinical diagnostic use. 48 
 49 
Global gene expression is most easily measured using cellular RNA (Nambiar et al., 50 
2005), however protein expression gives a more dynamic view, providing information on 51 
protein interactions, alternative splicing and post-translational modifications, as well as 52 
protein abundance (Maes et al., 2015). Global protein expression may therefore be of more 53 
use clinically than genomics, since it is proteins that perform most biological processes.  54 
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 55 
Most genomic and proteomic profiling studies focus on tumour tissue, however, 56 
since biopsy samples can be time consuming, stressful and expensive to obtain, the use of  57 
tumour biomarkers in blood or other body fluids (urine, cerebrospinal fluid) for diagnosis and 58 
monitoring of treatment response is an attractive tool for clinicians (McCaw et al., 2007). In 59 
addition, circulating tumour DNA released from tumour cells in the blood can reflect the 60 
genomic changes in the tumour itself and is an exciting prospect for determining tumour gene 61 
expression from the blood (Schaefer et al., 2007; Forshew et al., 2012; Bidard et al., 2013). 62 
 63 
This review will summarise recent developments in genomic and proteomic 64 
profiling of canine tumour tissue and blood, which could be of value in diagnosis and 65 
therapeutic decisions. It includes the most relevant publications, but is not an exhaustive list 66 
of all veterinary studies using genomic and proteomic profiling. 67 
 68 
Genomic Profiling - techniques 69 
Sequencing of the canine genome (Lindblad-Toh et al., 2005) and more recent 70 
improvements in genome detail (Hoeppner et al., 2014)  have facilitated high throughput 71 
genomic or gene expression profiling (GEP) of canine tumour tissues.  72 
 73 
Initial global gene expression studies in dogs used microarray techniques whereby 74 
extracted RNA was converted to a fluorescently labelled cDNA and hybridised to DNA 75 
coding sequences attached to a solid surface platform (Nambiar et al., 2005); either cDNA 76 
fragments (Buishand et al., 2013) or short synthesised oligonucleotide segments (25-60bp) 77 
representing the whole canine genome (Klopfleisch et al., 2010b; Scott et al., 2011). The 78 
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location and intensity of the cDNA identified which genes were expressed and their level of 79 
expression (Nambiar et al., 2005). 80 
 81 
Since microarray techniques rely on hybridisation between nucleic acids, cross-82 
hybridisation makes analysis of highly related sequences difficult, prior knowledge of gene 83 
sequences being investigated is necessary to attach these to the array, and detection of low 84 
abundance genes is difficult (Shendure, 2008). More recently, massively parallel sequencing 85 
of nucleic acids (next generation sequencing, NGS) has proved more popular because it does 86 
not rely on hybridisation and provides extra information on splice variants, polymorphisms 87 
and possible mutations. Interpreting the significance of mutations can be challenging, 88 
however, since many are bystander mutations which do not lead to cell transformation and in 89 
addition, redundancy in cancer pathways means that the biological impact of gene 90 
modifications is not always immediately apparent as an oncogenic effect. For transcriptomic 91 
NGS (RNA-Seq), RNA is converted to cDNA fragments, adaptors are attached to one 92 
(single-end sequencing) or both ends (pair-end sequencing) and fragments are sequenced to 93 
give reads of 30-400base pairs depending on the technology used. Resulting reads are either 94 
compared to a reference genome or assembled without the genomic sequence to give detail of 95 
gene expression and transcript structure.  With decreasing costs, NGS is now preferred over 96 
microarray methods (Wang et al., 2009), although both techniques require enormous 97 
bioinformatic input for manipulation and interpretation of the data.  98 
 99 
Genomic profiling - common veterinary tumour types 100 
GEP has been conducted in a variety of canine tumour types (Table 1), although the 101 
data obtained are not yet in diagnostic use in most cases. 102 
 103 
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Lymphoma  104 
Conventional diagnosis of canine lymphoma is based on either cytological or 105 
histological interpretation of cell morphology and architecture, often using  human 106 
classification systems (Teske et al., 1994; Fournel-Fleury et al., 1997; Vezzali et al., 2010; 107 
Valli et al., 2011). Application of the revised WHO classification scheme has identified the 108 
most common canine subtypes as being diffuse large B cell (DLBCL; 48%), peripheral T cell 109 
lymphoma not otherwise specified ( PTCL-NOS; 14%), T-zone lymphoma (13%; TZL), T-110 
cell lymphoblastic lymphoma (T-LBL; 4%) and marginal zone lymphoma (4%; MZL) (Valli 111 
et al., 2011) although additional criteria such as phenotype, cytogenetic and molecular 112 
changes are rarely available for dogs as part of their routine diagnostic investigations.  113 
 114 
Molecular profiling of canine lymphoma is still in its infancy, however, a microarray 115 
analysis of 35 lymphomas of the six most common subtypes ( Frantz et al., 2013) was able to 116 
split the tumours into B  (DLBCL, MZL, Burkitt and Burkitt-like lymphoma [BL]) and  T 117 
cell phenotypes (T -LBL, TZL, PTCL-NOS) according to gene expression. Furthermore a 118 
clear difference in gene signature split the T cells into low and high grade tumours but the B 119 
cell tumours were less easily separated. Mindful of the need for their data to be diagnostically 120 
relevant, the researchers developed a benchtop diagnostic test based on qRT-PCR of four 121 
genes that could reliably classify an independent cohort of 17 canine lymphomas into the 122 
three main subgroups. To distinguish B or T phenotype, the ratio of CD28 to ABCA5 123 
expression was calculated with a value of >1 indicating T cell, and <1 indicating B cell.  To 124 
separate each T cell tumour according to grade, the expression ratio for CCDC3 to SMOC2 125 
was calculated with a value of >1 indicating low grade T cell tumour and <1 indicating high 126 
grade.  Although technically possible to carry out qRT-PCR within the scope of a diagnostic 127 
laboratory, it remains to be seen whether this gene expression test is adopted commercially.  128 
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 129 
 Other research groups have focussed on molecular subtyping of DLBCL, the most 130 
common subtype in both dogs and man. Human DLBCL is further divided into activated B 131 
cell (ABC) or germinal centre B cell (GCB) on the basis of gene expression, an important 132 
prognostic classification with only 16% of ABC patients alive at 5 years compared to 76% of 133 
GCB patients (Richards et al., 2013; Richards and Suter, 2015). The ABC subtype is 134 
characterised by B cell receptor pathway signalling and constitutive canonical NF-kB activity 135 
and a similar subtype with NF-kB activity has been identified in dogs (Gaurnier-Hausser et 136 
al., 2011; Mudaliar et al., 2013; Richards et al., 2013). Although the gene signatures that 137 
typically separate human ABC and GCB DLBCL do not separate dog DLBCL as reliably, the 138 
pathways and biologic processes that distinguish GC and post GC groups are shared between 139 
species (Richards et al., 2013). A canine specific set of differentially expressed genes 140 
separates two distinct groups with significantly different survival as do IgH somatic 141 
hypermutations (ongoing or static). Immunohistochemical algorithms based on antigens 142 
expressed by GC or post GC cells (CD10, BCL6 and MUM1) are used to identify the 143 
ABC/GCB subtypes in man as a diagnostically more useful surrogate for GEP, however, in 144 
dogs IHC seems less useful since only CD10 stained a moderate number of DLBCL samples, 145 
with BCL6 and MUM1/IRF4 rarely expressed (Richards et al., 2013). Unfortunately this 146 
means diagnostic application of DLBCL subtyping by IHC will be more complicated in the 147 
dog until new markers can be identified and tested.  148 
 149 
The molecular classification of canine lymphoma holds promise for future 150 
therapeutic developments. Intra-nodal injection of an NF-º B essential modulator-binding 151 
domain peptide in four dogs with relapsed DLBCL expressing NF-º B, produced a marked 152 
reduction in tumour mass in three cases by inhibiting NF-º B expression (Gaurnier-Hausser et 153 
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al., 2011), and oral administration of the bruton tyrosine kinase inhibitor PCI-32765 154 
(ibrutinib) to block B cell receptor signalling in eight treatment naïve or relapsed lymphoma 155 
dogs produced a partial response (3/8) or stable disease (3/8) (Honigberg et al., 2010). Thus 156 
with more accurate classification of canine tumours based on gene expression, more tailored 157 
and targeted drug therapy should be possible for individual patients.  158 
 159 
Mammary tumours 160 
GEP of canine mammary tumours is still in its infancy but has much potential when 161 
compared to molecular classification of human breast cancer. Although the IHC detection of 162 
oestrogen receptor (ER), progesterone receptor (PR), and Human epidermal growth factor 163 
receptor 2 (HER2) in human breast cancer has been routine diagnostic practice for decades to 164 
assist with prognosis and therapeutic intervention, genomic profiling has greatly refined their 165 
usage. GEP of human breast tumours using microarray analysis first identified four major 166 
groups with different gene signatures: luminal, HER2 enriched, basal-like and normal (Perou 167 
et al., 1999; Perou et al., 2000). Subsequent studies split the luminal group into luminal A 168 
(high ER expression) and luminal B (low to moderate ER expression), and showed gene 169 
expression patterns could be linked to overall survival, disease relapse, metastasis and 170 
chemotherapy response (Toss and Cristofanilli, 2015). Since then, these molecular subtypes 171 
have been adopted in routine clinical practice, but for ease of clinical diagnostics, they are 172 
identified using the three basic IHC markers, with treatment tailored accordingly e.g. 173 
endocrine therapy for luminal A and B, and HER2 therapy for HER2-enriched. The basal-like 174 
subtype, recognised as carrying a poor prognosis was originally defined as being triple (ER, 175 
PR, HER2)-negative (TN), but more recently it has been emphasised that the two terms are 176 
not synonymous, with basal-like tumours forming only a proportion of triple negative 177 
tumours (Foulkes et al., 2010). Molecular classification of TN tumours has identified six gene 178 
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expression subtypes: two basal-like, an immunomodulatory, a mesenchymal, a mesenchymal 179 
stem-like and a luminal androgen receptor (AR) subtype (Lehmann et al., 2011; Turner and 180 
Reis-Filho, 2013). Since the AR luminal subtype has a better overall survival, it is important 181 
to distinguish these from basal-like tumours especially since recent clinical trials with 182 
androgen receptor antagonists have shown therapeutic benefit. 183 
 184 
Since malignant canine mammary tumours share many clinical properties with their 185 
human counterparts, several IHC studies have examined whether the same molecular 186 
subtypes can be identified in dogs. One study (Gama et al., 2008) used an IHC panel based on 187 
five markers (ER, HER2, cytokeratin 5, p63 and P-cadherin) to evaluate 96 malignant 188 
carcinomas (simple or complex) and carcinosarcomas and identified the four main human 189 
subtypes: luminal A (44.8%), luminal B (13.5%), HER2 (8.3%) and basal (29.2%). In 190 
contrast, a smaller IHC study on 44 mammary carcinomas (simple or complex) and one 191 
squamous cell carcinoma identified luminal A and B and basal subtypes, but no HER2 192 
enriched tumours (Sassi et al., 2010). The basal subtype was associated with a poor prognosis 193 
(shorter overall and disease-free survival) in the first, but not the second study. A more recent 194 
study focussed on canine mammary tumours which were phenotypically TN in an attempt to 195 
distinguish these from the basal-like breast cancer molecular subtype (Kim et al., 2013). Of 196 
the 45 TN tumours (33 simple or mixed carcinomas and 12 special types) examined, 43 197 
expressed at least one basal marker (CK14, 5/6, p63 or EGFR), and 34 expressed more than 198 
two markers and were therefore considered to have a basal-like phenotype with a worse 199 
prognosis (Kim et al 2013). Although these three studies show that there may be some 200 
overlap of the molecular subtypes between dog and man, it has yet to be shown that the full 201 
molecular signatures are similar between the two species. More studies, as well as 202 
standardisation of methodologies in terms of antibody clone and dilution, and antigen 203 
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retrieval treatment are needed before diagnostic laboratories are likely to adopt IHC with 204 
these markers as routine procedure. While subtyping of human breast tumours determines 205 
treatment selection, the benefit of anti-estrogens and antiHER2 therapy has not been 206 
established in dogs, meaning that subtyping may have less therapeutic value in this species. 207 
 208 
GEP studies on small numbers of canine mammary tumours have been conducted; 209 
however, data are limited and have not yet translated to routine diagnosis. Using a dog 210 
specific cDNA microarray, one study examined gene expression in 21 mammary tumours 211 
compared to normal tissue and progesterone-induced mammary hyperplasia (Rao et al., 212 
2009). The mammary tumours differentially expressed genes involved in cell motility, 213 
cytoskeleton organisation and extracellular matrix production, although the expression 214 
signatures of benign (n = 4) and malignant (n = 17) tumours, which might be of more use 215 
diagnostically, were not compared (Rao et al., 2009). A microarray study on 18 mammary 216 
carcinomas compared gene expression to histological grade (Pawlowski et al., 2013b). Five 217 
key genes were identified as being either upregulated (sehrl, mipep, relaxin) or 218 
downregulated (magi3, zfp37) in high grade tumours, and protein expression was verified by 219 
IHC to demonstrate that this gene set has potential to distinguish high grade malignancy 220 
(Pawlowski et al., 2013c). Using different microarrays, the same researchers also compared 221 
six low and six high grade tumours and found that poorly differentiated tumours often contain 222 
upregulated chemokine and cytokine mediated signalling pathways (Pawlowski et al., 2013a), 223 
consistent with conventional histological grading of tumours which often takes into account 224 
presence of inflammatory response as one criterion of malignancy (Ehrhart et al., 2013). 225 
Although canine metastatic carcinomas can be differentiated from both normal mammary 226 
gland and non-metastatic carcinomas by global gene expression (Klopfleisch et al., 2010b, 227 
2011), a small number of key genes that could be detected by IHC in a diagnostic setting to 228 
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predict metastatic potential, has not been finalised as yet. Further microarray studies on 229 
isolated populations of cancer cells separated from background stromaare needed to clarify 230 
the genetic contribution of each cell type to breast cancer progression.  231 
 232 
Canine mammary tumours may be complex (epithelial and myoepithelial 233 
components) or mixed (osseocartilaginous) as well as forming simple carcinomas as in 234 
human breast cancer and the underlying molecular mechanisms for each still need to be 235 
established.. Using paired-end whole genome sequencing, whole-exome sequencing and 236 
RNA-seq, Liu et al (2014) showed that while mammary carcinomas have extensive genomic 237 
aberrations, complex tumours contain mostly epigenomic aberrations (Liu et al., 2014). A 238 
further study using microarray analysis separated gene expression of canine mammary 239 
carcinomas from sarcomas and identified homeobox genes as overexpressed in the latter 240 
(Wensman et al., 2009). Such studies may have diagnostic potential in particularly 241 
undifferentiated tumours and further work may relate these gene signatures to prognosis or to 242 
key pathways for targeted chemotherapy. 243 
 244 
In human medicine, five commercial multi-gene profiling tests have been developed 245 
to analyse individual patient breast tumour samples and provide prognostic information based 246 
on more reliable, reproducible and less subjective techniques than IHC (Toss and 247 
Cristofanilli, 2015). Some just predict low or high risk e.g. MammaPrint (70 genes), but the 248 
Prediction Analysis of Microarray (PAM50–50 genes) and BluePrint (80 genes) determine 249 
the four major intrinsic subtypes (Luminal A/B, HER2-enriched or basal-like) which is 250 
helpful for treatment decisions and prognosis. The comparative predictive value of these tests 251 
is still being evaluated in independent clinical trials. Ultimately, similar tests could be 252 
developed for dogs, if GEP of mammary tumours reveals defined subtypes.  253 
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 254 
Soft tissue sarcomas 255 
Peripheral nerve sheath tumours (PNST) and fibrosarcomas (FSA) can be difficult to 256 
distinguish by morphological characteristics alone or using IHC markers.  Klopfleisch et al 257 
(2013) therefore looked at gene expression in five PNST and five FSA using microarrays and 258 
identified 45 gene products that were differentially expressed (Klopfleisch et al., 2013). 259 
Seven genes known to be specifically expressed in neuroectodermal tissues were upregulated 260 
in PNSTs compared to eight genes associated with carcinogenesis which were more highly 261 
expressed in FSA. Interestingly, when the same group tried to validate RT-PCR assays for 262 
these genes to differentiate PNST from FSA which had been classified using conventional 263 
IHC markers (S100, laminin and PGP9.5), the potential PNST markers GLI1 and CLEC3B 264 
were able to differentiate the two  tumour types with a sensitivity of 89% and specificity of 265 
87%, while the potential FSA markers FHL2-Ex4 and FHL2-Ex9 were unable to separate the 266 
tumour types reliably (sensitivity 50%, specificity 88%) (Meyer and Klopfleisch, 2014). 267 
 268 
As well as distinguishing between different types of soft tissue sarcoma, genomic 269 
profiling can assist subclassification within sarcoma types. Microarray analysis of 15 270 
Histiocytic sarcomas in the Flatcoated retriever identified nine genes that separated tumour 271 
from normal spleen (five downregulated;  four upregulated) (Boerkamp et al., 2013) but also 272 
identified further genes that were differentially expressed between the two clinical 273 
presentations of the disease: the soft tissue form affecting limb muscles and joints and the 274 
visceral form affecting internal organs with widespread dissemination (Boerkamp et al., 275 
2014).  qRT-PCR confirmed the differential expression of three genes: C6 upregulated and 276 
VLEC12A and CCL5 downregulated in the visceral compared to the soft tissue form. Whilst 277 
this could be adopted as a useful assay in a diagnostic laboratory, it is arguable that the two 278 
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forms of the disease are generally distinguished quite easily by clinicians, without the need 279 
for such a test.  280 
 281 
GEP of canine haemangiosarcomas has also helped identify tumour subtypes.  After  282 
candidate gene investigations had failed to show abnormalities in the PTEN/Akt pathway, 283 
VHL or Ras genes, microarray analysis was used to examine global gene expression of ten 284 
haemangiosarcoma samples cultured to enrich for endothelial cells prior to analysis and 285 
compared to four splenic haematomas (normal endothelium) (Tamburini et al., 2010). Gene 286 
expression data indicated that the two main processes central to the pathogenesis of canine 287 
haemangiosarcoma were inflammation and angiogenesis and it was hypothesised that, rather 288 
than the inflammatory component being recruited to the tumour microenvironment, it may be 289 
derived from a shared haematopoietic/endothelial progenitor i.e. a single lineage gives rise to 290 
both endothelial and haematopoietic progenitors. Subsequent genome-wide expression 291 
profiling of 24 canine haemangiosarcoma tissue samples using NGS supported the idea of a 292 
multipotent progenitor differentiating into three distinct subtypes: angiogenesis, inflammation 293 
and adipogenesis (Gorden et al., 2014). The three gene signatures were then validated in 47 294 
other tumour samples using RNA-seq analysis. It remains to be seen whether these subtypes 295 
have different clinical outcomes and whether diagnostic assays to differentiate them would be 296 
of value. 297 
 298 
Osteosarcoma 299 
Gene expression studies of canine osteosarcoma (OSA) have focussed on the 300 
comparative nature of the disease with its human counterpart. Microarray analysis of 15 dog 301 
and 15 paediatric osteosarcomas was not able to distinguish the human and canine diseases 302 
by their gene expression signatures and two genes consistently expressed in dog tissues (IL-8 303 
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and SLC1A3) were associated with a poor outcome in an independent group of children with 304 
OSA (Paoloni et al., 2009). The heterogeneous nature of the tumours has hampered genomic 305 
analysis, so another study of 26 OSA used low-passage cells lines to filter out stromal 306 
contributions (Scott et al., 2011). This identified two groups of tumours with robustly 307 
different gene signatures and which had significantly different survival times. The gene 308 
signatures were used to segregate reliably, further data sets from dogs and humans, 309 
suggesting there is potential for this to be applied in a diagnostic setting, if the key genes in 310 
the signature could be narrowed down. A previous microarray study on 32 OSA frozen tissue 311 
samples was also able to distinguish two groups based on long and short survival times with 312 
upregulated genes  in the short survivors involved in proliferation, drug resistance or 313 
metastasis (Selvarajah et al., 2009). 314 
 315 
Mast cell tumour 316 
Differentiation of low grade from high grade mast cell tumours (MCT) is difficult 317 
based on histological appearance alone despite the used of different grading systems (Kiupel 318 
et al., 2011; Patnaik et al., 1984). A recent microarray study of 51 canine MCT was unable to 319 
separate the samples clearly into well-defined groups on the basis of unsupervised gene 320 
expression clustering because of too much sample variability, however comparison of 321 
differentiated and undifferentiated tumours based on histological criteria, identified clear 322 
differences in gene expression relating to cell cycle, DNA replication, p53 signalling, 323 
nucleotide excision repair and pyrimidine metabolism (Giantin et al., 2014). The two groups 324 
had significantly different survival times, and four genes in particular, FOXM1, GSN, FEN1 325 
and KPNA2 were linked to MCT-related mortality. For practical diagnostic purposes, qRT-326 
PCR assays were developed for 13 transcripts which most reliably separated differentiated 327 
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and undifferentiated tumours, and the authors suggest these could be developed as a useful 328 
and cheap benchtop diagnostic test to predict MCT outcome regardless of histological grade.  329 
 330 
Proteomic profiling - techniques 331 
Protein expression profiling in clinical practice has lagged behind genomic 332 
techniques in both human and veterinary fields (Kycko and Reichert, 2014; Maes et al., 2015) 333 
but has great potential, particularly in identifying cancer biomarkers to assist with diagnosis, 334 
treatment selection and monitoring of patients.   335 
 336 
To detect proteins of both high and low abundance, protein extracts must be 337 
fractionated using techniques such as liquid chromatography (LC) or gel electrophoresis (GE) 338 
(Maes et al., 2015; Matharoo-Ball et al., 2008). Two dimensional polyacrylamide gel 339 
electrophoresis (2D-PAGE) which separates according to charge (isoelectric focusing) before 340 
molecular weight achieves better resolution than 1D-PAGE. To identify the separated 341 
proteins, bands or spots visualised by staining are excised, digested with proteases to small 342 
fragments which are then ionized and analysed by mass spectrometry (MS). Electrospray 343 
ionization (ESI) is usually combined with LC in tandem (LC-MS/MS) whereas matrix-344 
assisted laser desorption/ionization (MALDI) or surface enhanced laser desorption/ionization 345 
(SELDI) are often combined with time-of flight (TOF) MS. The peptide sequences obtained 346 
by MS are matched to known protein databases to identify the relevant proteins in a ‘bottom-347 
up’ approach. The alternative ‘top-down’ approach in which intact proteins are identified 348 
without prior enzymatic digestion (Gregorich and Ge, 2014) results in reduced sample 349 
complexity but suffers from molecular weight limitations in protein solubility, separation and 350 
MS analysis (Matharoo-Ball et al., 2008; Gregorich and Ge, 2014).  351 
 352 
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To overcome the low throughput limitations of 2D-PAGE (one sample on one gel), 353 
two dimensional differential gel electrophoresis (2D- DIGE) has been developed, in which 354 
two samples and an internal control are labelled with different fluorescent cyanine dyes, then 355 
run together on a single gel to allow the ratio of the sample proteins to be determined at each 356 
separated spot on the gel (Matharoo-Ball et al., 2008; Maes et al., 2015).  357 
 358 
Proteomic Profiling – common veterinary tumour types 359 
A limited number of veterinary studies have used proteomics (Table 2), most 360 
comparing gene expression in tumour to normal tissue. Formalin fixed paraffin embedded  361 
sections are less reliable than fresh-frozen tissue, particularly for the high molecular weight 362 
subproteome (Tanca et al., 2012; Tanca et al., 2013).  Blood and other body fluids including 363 
dog tears have also been examined in the search for biomarkers to diagnose and monitor 364 
cancer patients (de Freitas Campos et al., 2008). 365 
 366 
Lymphoma 367 
Tissue 368 
Only one study has examined canine lymphoid tissue using proteomics, comparing 369 
11 lymph nodes from dogs with B cell lymphoma to 13 from normal dogs using 2D-PAGE.  370 
Ninety-three differentially expressed  spots analysed by MALDI-TOF MS revealed three 371 
down regulated (prolidase, triosephosphate isomerase and glutathione S transferase) and one 372 
upregulated protein (macrophage capping protein) in lymphoma (McCaw et al., 2007). 373 
Further studies are needed to confirm whether these proteins could represent potentially 374 
useful biomarkers for diagnosis or classification. 375 
 376 
Blood 377 
17 
 
In contrast, several proteomic studies have examined serum from dogs with 378 
lymphoma. One, comparing serum samples from 29 dogs with B cell lymphoma and 87 379 
control dogs (healthy, with non-cancer diseases, or non-lymphoma cancers) using ion 380 
exchange chromatography and SELDI-TOF MS identified three protein peaks with biomarker 381 
potential (Gaines et al., 2007). These separated the lymphoma cases from the controls in a 382 
classification tree with positive and negative predictive values of 78% and 99% (97% 383 
sensitivity, 91% specificity, 92% accuracy), however the identity of the proteins was not 384 
given. 385 
 386 
A second larger study using the same proteomic technique compared serum samples 387 
from 87 lymphoma patients and 92 non-lymphoma samples (diseased or healthy). Although 388 
19 serum peaks were differentially expressed, two biomarkers in particular were able to 389 
differentiate control and lymphoma patients and when tested on a separate cohort of 96 390 
patients gave positive and negative predictive values of 80% and 88% (sensitivity 75%, 391 
specificity 91%) (Ratcliffe et al., 2009). These were later revealed as the acute phase proteins, 392 
haptoglobin and C-reactive protein (CRP) which have been combined with a unique 393 
algorithm to produce the canine lymphoma blood test (cLBT) (Alexandrakis et al., 2014). 394 
Although these proteins are not specific to lymphoma, the cLBT score appears useful in 395 
predicting prognosis and monitoring remission status whilst on treatment and is marketed as a 396 
commercial diagnostic test (Avacta) for lymphoma.  397 
 398 
Using a different 2D gel-based approach combining agarose and PAGE techniques 399 
with MALDI-TOF MS, another study (Atherton et al., 2013) examined the sera of three 400 
lymphoma cases compared to two normal healthy dogs. Ten proteins were identified in at 401 
least one lymphoma case but not in control dogs, with haptoglobin detected in all three 402 
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lymphoma cases. Other acute phase proteins, ±2 macroblobulin, inter-±-trypsin inhibitor and 403 
±-chymotrypsin were identified in lymphoma patients, consistent with an inflammatory 404 
component being present. Kininogen was present in control sera but absent from all three 405 
lymphoma cases. Although interesting, the data need to be verified in a larger cohort of dogs 406 
to see whether these proteins have diagnostic potential in the clinical setting.  407 
 408 
Another small study on three dogs with lymphoma, two with transitional cell 409 
carcinomas of the bladder and seven control dogs, looked specifically at serum glycoproteins 410 
using lectin affinity capture prior to global internal standard technology (GIST) stable isotope 411 
labelling, LC and MALDI-TOF MS (Wilson et al., 2008). Eleven fucosylated proteins were 412 
common to all three dogs with lymphoma and upregulated over 50% compared to controls.  413 
In one dog, the fucosylated protein levels fluctuated in response to chemotherapy treatment, 414 
suggesting the potential for disease monitoring. Further studies are needed, however, before 415 
these proteins can be used diagnostically.  416 
 417 
Mammary tumours 418 
Tissue 419 
To search for protein expression differences between long and short survivors with 420 
mammary tumours,  Klopfleisch et al (2010) compared the proteome of six mammary 421 
carcinomas with lymph node metastasis at presentation (survival time < six months) to six 422 
mammary carcinomas without metastasis at presentation (metastasis-free survival time > two 423 
years). Using 2D-DIGE and MALDI-TOF MS, they identified 11 upregulated and ten 424 
downregulated proteins in metastatic tumours, 19 of which were reported previously in 425 
metastatic human tumours including breast (Klopfleisch et al., 2010a).  Most proteins were 426 
involved in cellular functions related to metastatic spread such as proliferation, cell adhesion, 427 
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extracellular matrix remodelling, and hypoxia resistance.  In a similar study comparing six 428 
normal, six benign, six non-metastatic and six metastatic carcinomas, step wise changes in 429 
protein expression were identified, with the biggest change in protein expression detected by 430 
the switch to metastasis (Klose et al., 2011). Eleven of 48 proteins increased in metastatic 431 
tumours were involved in proliferation (PCNA, RAN binding protein 1, phosphoglycerate 432 
mutase 1, siderophilin and Rho-GTPase activating protein) and cell motility (tropomyosin 1 433 
and 3, myosin light chain 2, gelsolin and calumenin) and have been identified in the previous 434 
proteomic or genomic studies (Klopfleisch et al., 2010a; Rao et al., 2009), suggesting they 435 
are promising candidates for prognostic markers or therapeutic targets. 436 
 437 
Blood 438 
In a slightly different approach, serum from 15 dogs with mammary tumours and 15 439 
healthy controls (Zamani-Ahmadmahmudi et al., 2014) was hybridised by western blot to a 440 
membrane transferred from a 2D-PAGE gel on which proteins extracted from a mammary 441 
tumour cell line had been separated. Four immunoreactive autoantigens (manganese-442 
superoxide dismutase, triose phosphate isomerase, alpha-enolase, phosphoglycerate mutase1)  443 
were identified by cutting out spots from the original gel and subsequent MALDI-TOF MS, 444 
and all four showed higher expression in tumour tissue compared to control samples using 445 
IHC and western blotting and stimulated autoantibody responses in human breast cancer. 446 
Further work is needed to determine whether these proteins are useful in diagnostic 447 
classification or as prognostic biomarkers in dogs. 448 
 449 
Prostatic tumours 450 
Tissue 451 
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A 2D-DIGE and MALDI-TOF MS  study of three canine prostatic tumours 452 
compared them to normal prostate or bladder and identified nine proteins differentially 453 
upregulated over 2.5 fold; three being significantly overexpressed: keratin 7, glucose-454 
regulated protein GRP78 and endoplasmin (GRP74)  (LeRoy et al., 2007). Keratin 7 assists 455 
classification of anaplastic human prostatic neoplasms that are of transitional origin, so has 456 
diagnostic potential for the dog. A previous IHC study in dogs, however, did not find it 457 
helpful to discriminate prostatic neoplasms from transitional cell carcinoma (LeRoy et al., 458 
2004) although others found it correlated with castration status in younger dogs (Sorenmo et 459 
al., 2003). 460 
 461 
Mast cell tumours  462 
Tissue 463 
In an attempt to find better diagnostic methods to subclassify canine MCT, a 464 
proteomic study using 2D-DIGE and MALDI-TOF MS  identified 13 proteins which were 465 
differentially expressed, with four stress response proteins upregulated in high grade tumours, 466 
and proteins associated with cell motility and metastasis either increased or decreased 467 
(Schlieben et al., 2012). Only five low and five high grade tumours were examined but their 468 
grade was confirmed using both Kiupel and Patnaik grading systems and reduced expression 469 
of tryptase on proteomic analysis of the high grade tumours was consistent with their 470 
dedifferentiation. This proteomic study was performed prior to the genomic study discussed 471 
above (Giantin et al., 2014), however, there was no overlap in the genes identified by the two 472 
different methodologies.  Further studies are needed to find proteins that reliably differentiate 473 
the biological grade of mast cell tumours and can be used in clinical diagnosis. 474 
 475 
Conclusion 476 
21 
 
Although case numbers are small, the existing genomic and proteomic canine studies 477 
have already identified key genes and gene signatures which have potential for diagnostic 478 
use. Further validation of these marker genes on more clinical samples is now needed before 479 
applying them to diagnostic use in clinical pathology laboratories. Although progress is slow, 480 
the possibility of individualised patient care based on molecular or proteomic profiling of 481 
clinical samples may become reality in the not-too-distant future. 482 
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Table 1 733 
Veterinary studies using genomic profiling. 734 
 735 
Tumour 
type 
Cases Technique Findings Reference 
LSA 17 T cell 
17 B cell 
1 nonT-nonB cell 
Microarray 
Canine genome 
2.0 GeneChip a  
GEP separates B and T cell tumours and low 
and high grade T cell tumours. 
Ratio CD28:ABCA5 >1  predicts T cell 
Ratio CCD3:SMOC2 <1  predicts High grade 
T 
Frantz et al. 
(2013) 
LSA 58 B cell  
 
Microarray 
Canine genome 
2.0 GeneChip a  
Two separate groups of DLBCL with different 
progression free and overall survival times, 
similar to ABC and GCB subtypes in human 
DLBCL 
Richards et 
al. (2013) 
LSA 23 DLBCL 
10 normal LNs 
Microarray 
Canine genome 
2.0 GeneChip a 
NF-kBp65 canonical pathway activated as in 
human DLBCL 
Mudaliar et 
al. (2013 
MT 21 tumours (4 benign, 
17 malignant) 
8 normal mammary 
tissue 
8 progesterone-induced 
hyperplasia 
Microarray 
Dog specific 
cDNA 
Tumours had ‘  expression of ECM, cell 
motility and invasion genes (FN1, SPARC, 
CTHRC1, FHL2) and “ expression of 
cytoskeletal organisation genes (DES, ACTN1, 
NEB, DAG1) 
Rao et al. 
(2009) 
MT 18 CA  (6 well, 6 
moderately, 6 poorly 
differentiated) 
Microarray 
Dog specific 
cDNA (as in 
Rao et al, 2009) 
High grade CA have ‘  expression of Sehrl, 
mipep, relaxin and “ expression of Magi3, 
zfp37  
  
Pawlowski 
et al. (2013b, 
2013c) 
MT 12 CA  (6 well, 6 
poorly differentiated) 
Microarray 
Oligo- 
microarrayb 
High grade CA express myeloid specific 
antigens and have ‘  expression of chemokine 
and cytokine mediated pathways (e.g. S100P), 
and ECM/inflammatory response genes 
(MMP1 and 3)   
Pawlowski 
et al. 
(2013a) 
MT 13 LN +ve simple CA 
14 LN –ve simple CA 
Microarray 
Canine genome 
2.0 GeneChip a  
Metastatic CA have ‘  expression of cell cycle, 
matrix modulation, protein folding and 
proteasomal degradation genes and “ 
expression of cell differentiation, growth 
factor pathway and actin organization genes  
Klopfleisch 
et al. (2010) 
MT 13 LN +ve simple CA 
12 corresponding 
normal glands 
Microarray 
Canine genome 
2.0 GeneChip a 
Metastatic CA have ‘ cell division and  
invasion genes (MMP, SERPINE1, TIMP3) 
and“ differentiation (EGF, EGFR, MAP2K6, 
STAT 5), cell adhesion (CLDN5, CTNNAL1, 
MUC1, PECAM1), angiogenesis (ANGPT 2, 
ANGPTL1-4, FIGF, TIE1) and membrane 
receptor (EGFR, FGFR1, GHR, PDGFR, 
TGFBR, TIE1) genes  
Klopfleisch 
et al. (2011) 
MT 7 simple  CA 
4 complex CA 
 
NGS C Extensive genomic aberrations in simple CA.  
Epigenomic changes in complex CA.  
Liu et al. 
(2014) 
MT 7 simple CA 
6 FSA 
5 OSA 
4 normal tissues 
Microarray 
Canine genome 
2.0 GeneChip a  
CA expressed epithelial markers and cell 
adhesion genes. SA expressed mesenchymal 
differentiation genes and homeobox genes 
previously linked to craniofacial bone 
formation 
Wensman et 
al. (2009) 
STS 5 FSA 
5 PNST 
Microarray 
Canine genome 
2.0 GeneChip a  
Neuroectodermal genes (FMN2, KIF1B, GLI1, 
ROBO1, NMUR2, DOK4 and HMG20B) ‘  in 
PNSTs.  Carcinogenesis genes (FHL2, 
PLAGL1, FNBP1L, BAG2, HK1, CSK and 
Cox5A) ‘  in FSAs 
Klopfleisch 
et al. (2013) 
HisSA  
(FCR) 
7 visceral tumours 
6 soft tissue (limb) 
Microarray 
Canine Gene 
PPBP, SpiC, VCAM1, ENPEP, ITGAD “ and  
GTSF1, Col3a1, CD90 and LUM ‘  in both 
Boerkamp et 
al. (2013) 
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tumours  
6 normal spleen 
Expression V1 b forms of HisSA compared to normal tissue 
HisSA 
(FCR) 
8 visceral tumours 
7 soft tissue (limb) 
8 pooled normal organs 
Microarray 
Canine Gene 
Expression V1 b 
C6 was ‘  and CLEC12A and CCL5 were “ in 
the visceral compared to the soft tissue form 
Boerkamp et 
al. (2013) 
HSA 10 tumour samples 
4 non tumour   (low 
passage cell culture) 
Microarray 
Canine genome 
2.0 GeneChip a  
‘  of genes involved in inflammation, 
angiogenesis, adhesion, invasion, metabolism, 
cell cycle, signaling, and patterning. 
Tamburini et 
al. (2010) 
HSA 12 tissue samples & 18 
cell lines (microarray) 
35 tissue samples  
(NGS),  12 samples 
(microarray and NGS) 
Microarray 
Canine Gene 
Expressionb and 
NGSC 
Three distinct tumor subtypes associated with 
angiogenesis (group 1), inflammation (group 
2), and adipogenesis (group 3). Possibly a 
common progenitor. 
Gorden et al. 
(2014) 
OSA 15 dog tumours 
15 human tumours 
Microarray 
Canine genome 
v1.0 Human 
Genome  
U133Aa  
Expression signatures could not distinguish 
the canine and human diseases 
Paoloni et al. 
(2009) 
OSA 32 tumours Microarray 
Dog specific 
cDNA 
Gene expression identifies two prognostic 
groups based on survival time < or >6 months.  
‘  of proliferation, drug resistance or 
metastasis genes  in short survivors 
Selvarajah et 
al. (2009) 
OSA 26 low passage cell 
lines 
1 osteomyelitis 
6 tumours 
Microarray 
Canine genome 
2.0 GeneChip a  
Differential gene expression segregates dog 
samples into two groups with differential 
survival probabilities  and applies to human 
datasets 
Scott et al. 
(2011) 
MCT 51 tumours 
(5 undifferentiated, 13 
differentiated reference 
samples) 
Microarray 
Canine Gene 
Expression V2b  
13 genes involved in cell cycle, DNA 
replication, p53 signaling pathway, nucleotide 
excision repair and pyrimidine metabolism 
can separate undifferentiated and 
differentiated MCT.  
FOXM1, GSN, FEN1 and KPNA2 expression 
related to increased mortality 
Giantin et al. 
(2014)  
 736 
ABC – activated B cell, CA – carcinomas,  DLBCL -Diffuse large B cell, ECM –extracellular matrix,  FCR - 737 
flatcoated retriever, FSA-fibrosarcoma, GCB –germinal centre B cell, GEP- Gene expression profiling, LSA – 738 
lymphoma, MT – mammary tumour, HSA – haemangiosarcoma,  HisSA – histiocytic sarcoma,  MCT –mast cell 739 
tumour, SA – sarcomas, STS – soft tissue sarcoma,  NGS-next generation sequencing, OSA- osteosarcoma,  740 
PNST –peripheral nerve sheath tumour,  +ve  -positive,  -ve – negative,  ABCA5- ATP-Binding Cassette, Sub-741 
Family A (ABC1), Member 5; CCD3-cytoplasmic cluster of differentiation 3, SMO2-small organ 2, NF-kB – 742 
Nuclear factor kappa B;  FN1-fibronectin1; SPARC –secreted protein acidic cysteine rich, CTHRC1- Collagen 743 
Triple Helix Repeat Containing 1, FHL2 - Four And A Half LIM Domains 2, DES -desmin, ACTN1-actinin 744 
alpha 1, NEB -nebulin, DAG1-dystroglycan 1, MMP –matrix metalloproteinase, SERPINE1- Serpin Peptidase 745 
Inhibitor  Clade E, TIMP –tissue inhibitor of metalloproteinase, EGF –epidermal growth factor, EGFR –746 
epidermal growth factor receptor, MAP2K6- Mitogen-Activated Protein Kinase Kinase 6, STAT- signal 747 
transducer and activator of transcription, CLDN5-claudin 5, CTNNAL1- Catenin Alpha-Like 1, MUC1-mucin 1, 748 
PECAM1- Platelet/Endothelial Cell Adhesion Molecule 1, ANGPT 2- Angiopoietin 2, ANGPTL1-4- 749 
Angiopoietin-like 1-4, FIGF- C-Fos Induced Growth Factor, TIE1- Tyrosine Kinase With Immunoglobulin-Like 750 
And EGF-Like Domains 1, FGFR1 –fibroblast growth factor  receptor 1, GHR, PDGFR – platelet derived 751 
growth factor receptor, TGFBR –transforming growth factor  beta receptor, FMN2-formin 2, KIF1B- Kinesin 752 
Family Member 1B, GLI1- GLI Family Zinc Finger 1, ROBO1- Roundabout 1, NMUR2- Neuromedin U 753 
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Receptor 2, DOK4- Docking Protein 4, HMG20B- High Mobility Group 20B,  PLAGL1- Pleiomorphic 754 
Adenoma Gene-Like 1, FNBP1L- Fructose-1,6-Bisphosphatase 1-like, BAG2- BCL2-Associated Athanogene 2, 755 
HK1- Hexokinase 1, CSK- c-src tyrosine kinase, Cox5A- Cytochrome C Oxidase Subunit Va, PPBP- Pro-756 
Platelet Basic Protein, SpiC- Spi-C Transcription Factor, VCAM1- Vascular Cell Adhesion Molecule 1, 757 
ENPEP- Glutamyl Aminopeptidase, ITGAD- Integrin, Alpha D, GTSF1- Gametocyte Specific Factor 1, Col3a1- 758 
Collagen, Type III, Alpha 1, CD90-cluster of differentiation 90,  LUM-lumican, CLEC12A- C-type lectin-like 759 
domain family 12, member A  ,CCL5- Chemokine (C-C Motif) Ligand 5, FOXM1- Forkhead Box M1, GSN-760 
gelsolin, FEN1- Flap Structure-Specific Endonuclease 1, KPNA2- Karyopherin Alpha 2. 761 
a Affymetrix. 762 
b Agilent Technologies. 763 
c Illumina.  764 
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Table 2 766 
Veterinary studies using proteomic profiling. 767 
 768 
Tumour 
type 
Cases Technique Findings  Reference 
LSA Lymph nodes 
from  
11 B cell  
13 normal  
2D-PAGE and 
MALDI-TOF 
MS 
Prolidase (proline dipeptidase), triosephosphate 
isomerase, and glutathione S-transferase down-
regulated and  macrophage capping protein up-
regulated in lymphoma samples 
McCaw et 
al. (2007) 
LSA Serum from  
29 dogs –B cell 
87 dogs – healthy 
or nonLSA cancer 
IEC and 
SELDI-TOF 
MS 
Three biomarker protein peaks identified which 
could separate control from B cell lymphoma dogs 
Gaines et al. 
(2007) 
LSA Serum from 
87 dogs –LSA 
92 dogs – healthy 
or diseased 
IEC and 
SELDI-TOF 
MS 
Two biomarker protein peaks identified which 
could separate lymphoma and non-lymphoma 
patients. 
Ratcliffe et 
al. (2009) 
LSA Serum from 
3 dogs – LSA 
2 dogs –healthy 
Agarose and 
PAGE 
electrophoresi
s and MALDI-
TOF MS 
Haptoglobin identified in all three lymphoma dogs  
Kininogen absent in all three lymphoma dogs but 
present in the sera of healthy dogs 
Atherton et 
al. (2013) 
LSA Serum from 
3 dogs – LSA 
2 dogs – TCC 
bladder 
7 dogs - control 
LA capture 
GIST stable 
isotope 
labelling, LC 
and MALDI-
TOF MS 
11 fucosylated peptides ‘ by >50% in all 3 
lymphoma cases compared to normal. 
In one lymphoma case, 46 upregulated fucosylated 
peptides “ post-chemotherapy, and then 
subsequently ‘  upon recurrence and 9 ‘ post-
chemotherapy and “ upon recurrence 
Wilson et al. 
(2008) 
MT 6 LN +ve 
carcinomas  
(<6 months 
survival) 
6 LN –ve 
carcinomas 
(>2 years 
survival)  
 
2D-DIGE and 
MALDI-TOF 
MS 
Proteins ‘  in LN +ve carcinomas : proliferating cell 
nuclear antigen, ferritin light chain, bomapin, 
tropomyosin 3, thioredoxin-containing domain C5, 
adenosin, ornithine aminotransferase, coronin 1A, 
RAN-binding protein 1,3-phosphoglycerate 
dehydrogenase, & eukaryotic translation elongation 
factor 1.     Proteins “ in LN +ve carcinomas : 
calretinin, myosin, light chain 2, peroxiredoxin 6, 
maspin, ibrinogen beta chain, vinculin, isocitrate 
dehydrogenase 1, tropomyosin 1, annexin A5, and 
Rho GTPase activating protein 1 
Klopfleisch 
et al. (2010) 
MT 6 normal tissues 
6 adenomas 
6 LN –ve 
carcinomas  
6 LN +ve 
carcinomas  
2D-DIGE and 
MALDI-TOF 
MS  
Differences in malignancy are associated with a 
stepwise but not linear change in protein expression 
levels 
Acquisition of metastatic potential is associated 
with the strongest changes in protein expression 
levels 
Klose et al. 
(2011) 
MT Serum from 
15 dogs with 
tumours 
15 healthy 
controls 
Hybridisation 
to cell line sep 
by 2D-PAGE, 
and MALDI-
TOF MS 
Four autoantigens: manganese-superoxide 
dismutase, triose phosphate isomerase, alpha-
enolase, and phosphoglycerate mutase 1 with ‘  
immunoreactivity in tumour samples identified as 
biomarker candidates 
Zamani-
Ahmadmah
mudi et al. 
(2014) 
PT 3 prostate 
carcinomas 
6 normal prostate  
6 normal bladder 
2D-DIGE and 
MALDI-TOF 
MS 
Three proteins (keratin 7, GRP78, and 
endoplasmin) were ‘  in the carcinomas compared 
with normal prostate or bladder 
LeRoy et al. 
(2007) 
MCT 5 Low grade 
5 High grade 
2D-DIGE and 
MALDI-TOF 
MS  
Four stress response proteins (HSPA9, PDIA3, 
TCP1A, TCP1E) were ‘  in high-grade tumours.  
Proteins associated with cell motility and metastasis 
were either ‘  (WDR1, ACTR3, ANXA6) or “ 
(ANXA2, ACTB) 
Schlieben et 
al. (2012)  
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+ve   -positive,  -ve – negative, 2D-DIGE – 2 dimensional differential gel electrophoresis, 2D – PAGE - 770 
2dimensional polyacrylamide gel electrophoresis, GIST – global internal standard technology, IEC-Ion 771 
exchange chromatography,  LA – lectin affinity, LC – liquid chromatography,  LN –lymph node,  LSA- 772 
lymphoma, MCT –mast cell tumour,  MT-mammary tumour, PT-prostate tumour,  MALDI-TOF MS– matrix-773 
assisted laser desorption/ionisation with time of flight mass spectrometry, SELDI-TOF MS – surface-enhanced 774 
laser desorption/ionisation with time of flight mass spectrometry, sep-separated , TCC – transitional cell 775 
carcinoma,  GRP78-glucose regulated protein 78, HSPA9- Heat Shock 70kDa Protein 9 (Mortalin), PDIA3- 776 
Protein Disulfide Isomerase Family A, Member 3, TCP1A- T-complex polypeptide 1 alpha, TCP1E- T-complex 777 
polypeptide 1 epsilon, WDR1- WD Repeat Domain 1, ACTR3- Actin-Related Protein 3 Homolog, ANXA6-778 
annexin A6, ANXA2-annexin A6, ACTB-actin beta, RAN - RAs-related Nuclear protein. 779 
 780 
